Home›Stock Screener›Kwality Pharmaceuticals

Kwality Pharmaceuticals Share Price Today | Stock Price & Kwality Pharmaceuticals Share Screener

KPL Pharmaceuticals & Biotechnology
Live Share Price NSE
₹4207.90
▲ 161.60 (3.99%)
2026-11-18 00:00:00
Live Share Price BSE
₹4195.25
▲ 152.10 (3.76%)
2026-11-18 00:00:00

As of November 18, 2026, the live Kwality Pharmaceuticals share price (NSE: KPL) is ₹4,207.90 on NSE and ₹4,195.25 on BSE, up 3.99% from the previous close, with shares trading between ₹3,981.00 and ₹4,235.00 in today's trading session, and a 52-week range of ₹1,579.55–₹4,207.90. Track Kwality Pharmaceuticals market worth to gauge the company's total market size. Use the Kwality Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Kwality Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹158 and net income of ₹25, with EBITDA of ₹40, an operating margin of 25.0% and a profit margin of 15.8%.

Kwality Pharmaceuticals Market Cap ₹4,218.65 Cr.
KPL P/E Ratio (TTM) 43.80
Kwality Pharmaceuticals P/B Ratio 10.90
EPS (TTM) ₹64.90
Dividend Yield -
Debt to Equity 0.41
KPL 52 Week High ₹4207.90
Kwality Pharmaceuticals 52 Week Low ₹1579.55
Operating Margin 25.00%
Profit Margin 15.82%
KPL Revenue (TTM) ₹158.00
EBITDA ₹40.00
Net Income ₹25.00
Total Assets ₹592.00
Total Equity ₹330.00

Kwality Pharmaceuticals Share Price Chart

Track the current stock price of Kwality Pharmaceuticals with an interactive chart. Analyse KPL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Kwality Pharmaceuticals stock quote in one place.

The quote of ₹4,207.90 sits between the 52-week low of ₹1,579.55 and the 52-week high of ₹4,207.90, and the latest session moved 3.99% from the previous close.

Kwality Pharmaceuticals Company Profile - Fundamental Screener

Screen Kwality Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KPL shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE552U01010.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE552U01010

Kwality Pharmaceuticals Balance Sheet Screener

Screen KPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹592, up from ₹447 in 2025.

Latest statistics put total assets at ₹592 and shareholder funds at ₹330, with a leverage ratio of 0.41.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 592 447 394 354 341 166 133 105 96 71
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 156 146 139 121 92 57 43 29 20 17

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 37 15 20 29 21 28 20 8 6 4
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 330 262 223 199 180 60 45 36 29 25
Share Capital 10 10 10 10 10 10 10 10 10 5
Reserves & Surplus 321 254 214 190 171 51 36 27 19 20

Kwality Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Kwality Pharmaceuticals income statement and profit fundamentals. Analyze KPL quarterly results. Kwality Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹158 and net profit was ₹25, equal to earnings per unit of ₹24.39, at an operating margin of 25%.

In that period expenses were ₹118, interest cost ₹3 and tax ₹6. The next period listed, 2026-Jun, shows revenue of ₹163 and net profit of ₹26.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 158 163 182 117 112 112 124 93 80 90 85 70 68 70 79
Expenses 118 121 131 90 87 86 94 78 63 70 67 74 54 54 61

Operating Costs and Margins

EBITDA 40 42 51 27 25 26 30 14 18 20 18 -4 14 16 17
Operating Profit % 25.00% 25.00% 27.00% 22.00% 22.00% 23.00% 24.00% 15.00% 22.00% 22.00% 21.00% -7.00% 20.00% 22.00% 21.00%
Depreciation 5 5 5 5 5 5 5 5 4 5 5 4 5 5 5
Interest 3 3 3 3 3 3 3 3 3 3 2 2 2 2 3

Profit and Earnings

Profit Before Tax 32 34 42 19 17 19 22 6 11 13 11 -10 7 8 10
Tax 6 8 13 5 5 4 6 2 3 4 3 -2 2 2 2
Net Profit 25 26 29 15 12 14 16 4 8 9 9 -7 5 6 8
EPS 24.39 24.69 27.93 13.95 11.49 13.60 15.42 4.08 8.04 8.15 8.21 -7.23 5.10 5.99 7.39

Kwality Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen KPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹17, and net cash flow was an outflow of ₹11.

Over the same period, investing activities used ₹35 and financing activities provided ₹7.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 17 53 43 41 61 27 6 14 -1 4
Investing Activities -35 -29 -26 -48 -63 -23 -18 -12 -6 -7

Financing and Net Cash

Financing Activities 7 -14 -17 1 6 1 12 -2 5 5
Net Cash Flow -11 10 -1 -6 3 4 0 0 -1 2

Kwality Pharmaceuticals Shareholding Pattern Screener

See Kwality Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Kwality Pharmaceuticals promoter holding and ownership changes for KPL on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 54.87%, foreign institutions 2.79%, domestic institutions 0.36% and the public 31.64%, spread across 10,555 shareholders.

The shareholder count was 10,555 in 2026-Mar, compared with 13,279 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 54.87% 54.86% 54.86% 54.83% 54.83% 54.83% 54.83% 54.83%

Institutional Investors

FII Holding 2.79% 3.13% 2.50% 0.00% 0.00% 0.00% 0.50% 0.00%
DII Holding 0.36% 0.56% 1.07% 0.32% 0.33% 0.33% 0.33% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 31.64% 31.03% 31.26% 33.39% 33.32% 33.68% 33.02% 31.70%
Other Holding 10.35% 10.42% 10.31% 11.47% 11.52% 11.16% 11.32% 13.47%
Shareholder Count 10,555 13,279 17,880 9,420 10,115 11,595 10,709 5,695

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Kwality Pharmaceuticals. Kwality Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.60 1.46%

Kwality Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Kwality Pharmaceuticals stock. Check KPL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Kwality Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Kwality Pharmaceuticals Market Events Screener - Corporate Actions

Get Kwality Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Kwality Pharmaceuticals stock events that may affect KPL share price, along with derivatives, futures and options activity and sector gainers.

13 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 12, 2026, with a record date of November 12, 2026.

It is followed by Annual General Meeting dated August 31, 2026 and Quarterly Result Announcement dated August 10, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-12 2026-11-12 Quarterly Result Announcement NA 6.54%
2026-08-31 2026-08-31 Annual General Meeting NA 26.74%
2026-08-10 2026-08-10 Quarterly Result Announcement NA 1.00%
2026-05-19 2026-05-19 Quarterly Result Announcement NA 6.18%
2026-02-12 2026-02-12 Quarterly Result Announcement NA 8.46%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -1.90%
2025-09-09 2025-09-09 Annual General Meeting NA -11.48%
2025-08-11 2025-08-11 Quarterly Result Announcement NA 0.73%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 12.45%
2025-01-31 2025-01-31 Quarterly Result Announcement NA -2.47%
2024-10-30 2024-10-30 Quarterly Result Announcement NA -0.73%
2024-09-24 2024-09-24 Annual General Meeting NA 3.14%
2017-10-11 2017-10-12 Bonus 1:1 -

Kwality Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen KPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,915 40.80 61,674 12.69% 11,565 59.98
Divis Laboratories 295,467 87.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 177,137 85.00 13,886 20.34% 2,138 49.31
Laurus Labs 125,498 89.90 6,868 22.01% 890 49.19
Zydus Life Science 120,678 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,036 41.80 35,059 3.90% 4,158 69.34
Cipla 112,559 39.50 29,045 2.24% 3,870 55.82
Mankind Pharma 108,552 47.90 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,395 25.80 34,145 5.56% 3,503 60.38
Lupin 89,702 17.30 29,039 26.75% 5,356 44.23

Kwality Pharmaceuticals Company Announcements - News & Reports Screener

Screen KPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated and November 18, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Newspaper Publication -
Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-18 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-18 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-16 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-16 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s -
2026-11-16 Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors -
2026-11-16 Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2026 -
2026-11-16 Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2026 -
2026-11-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-11 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-05 Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. -
2026-11-04 EU-GMP Approval From Hungary For Cephalosporin And Oncology Facilities -
2026-10-19 Acquisition Of Land For Manuufacturing Expansion At Amritsar -
2026-10-10 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-28 Closure of Trading Window -
2026-09-02 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-02 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-31 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-13 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹4,207.90, within a 52-week range of ₹1,579.55 to ₹4,207.90. The P/E ratio is 43.80 and the P/B ratio is 10.90, with earnings per unit of ₹64.90. Market capitalisation stands at ₹4,218.65 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.